Combined oral contraceptives (COCs) are among the most widely used effective and reversible means of family planning. Their beneficial effects are well documented, but many questions are still raised concerning a possible association between the use of COCs and the development of cancer. The authors provide a broad and up-to-date review of the literature regarding the relation between COC use and carcinogenesis in different organs. Studies have not unequivocally confirmed that such a relation exists with regard to breast cancer. Much research focused on the influence COC use could have on the incidence of cervical cancer; most of it was analyzed by J. Smith and co-workers. These authors confirmed the existence of a weak relation between COC use and the development of cervical carcinoma, especially in women using COCs for longer periods. Ovarian carcinoma has the worst prognosis of all cancers of reproductive organs in women. The risk of developing ovarian cancer in women using COCs is at least 40% smaller than in other women; the degree of protection given by COCs is directly proportional to the duration of use of this form of contraception. Reliable scientific data prove convincingly that the risk of endometrial cancer is smaller in women who used COCs than in women who never took them.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13625180600815706 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Multimodal Approach to Symptomatic Endometriosis: A Proposed Algorithm for Clinical Management.
Reprod Sci
January 2025
Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Recent research has proven that peripheral (PS) and central sensitization (CS), mental health, and myofascial dysfunction all play a role, alongside nociception, in the genesis and in the perpetuation of endometriosis' symptoms. However, such components of pain are still largely ignored in clinical practice, although not considering such contributors may entail serious consequences on women's health, including the choice of unnecessary surgery and leaving the real causes of pain untreated. At the present time, we are facing a paradox by which 25-40% of women who undergo laparoscopic surgery for pelvic pain do not have an obvious diagnosis, while the percentage of women with endometriosis who have signs of CS, of depressive or anxiety disorders, or who have an increased pelvic muscle tone ammounts to 41-55%, 15-88% and 28-73%, respectively.
View Article and Find Full Text PDFBona fide diminished ovarian reserve or profound ovarian suppression by long-term oral contraceptive use?
BMJ Case Rep
January 2025
Obstetrics and Gynecology; Divison of Reproductive Endocrinology and Infertility, University of Toronto, Toronto, Ontario, Canada
Combined oral contraceptives (COCs) are widely used by reproductive-aged women. Current data suggest that long-term use of COCs can suppress ovarian reserve markers, including anti-mullerian hormone and antral follicle count, which may negatively impact ovarian response and oocyte yield in patients undergoing planned oocyte cryopreservation to preserve future reproductive potential. Discontinuation of COCs can improve ovarian stimulation outcomes, though the ideal duration of cessation is unknown.
View Article and Find Full Text PDFSafety and efficacy of pharmacotherapies for pelvic inflammatory disease and endometriosis.
Expert Opin Drug Saf
January 2025
Unit of Obstetrics and Gynecology, Genoa, Italy.
Introduction: Endometriosis and pelvic inflammatory disease (PID) are gynecological conditions affecting women of reproductive age and causing pain symptoms. The symptoms caused by these conditions are similar; thus, the differential diagnosis may be challenging. The treatment of these conditions is very different because PID is treated with antibiotic therapy, while endometriosis is treated with hormonal therapies suppressing estrogen levels.
View Article and Find Full Text PDFImpact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data.
Contraception
December 2024
LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany; Center for Translational Neuro and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany; Bielefeld University, Medical School and University Medical Center OWL, Protestant Hospital of the Bethel Foundation, Department of Psychiatry and Psychotherapy, Bielefeld, Germany.
Objectives: To assess the risk of contraceptive failure and adverse events (AEs) associated with the type of progestin when coadministered with psychotropic drugs within a routine clinical practice setting.
Study Design: A pooled analysis of four large, prospective, multinational cohort studies including women with a new prescription of combined oral contraceptives (COCs) and concomitant psychotropic drug use from 13 European countries and the United States. We determined the frequency of contraceptive failures and AEs within 6 months after COC initiation by progestin type.
Thrombomodulin is a stronger indicator of combined oral contraceptives-induced activated protein C pathway resistance in the thrombin generation test than activated protein C.
Front Cardiovasc Med
November 2024
Department of Data Analysis and Artificial Intelligence, Synapse Research Institute, Maastricht, Netherlands.
Background: The mechanism by which combined oral contraceptives (COCs) lead to hypercoagulation is not fully understood, although activated protein C (APC) pathway resistance has been implicated. APC and thrombomodulin (TM) tend to be considered as interchangeable reagents, even though their biological action in coagulation is different. However, it remains unclear which reagent is better suited for the detection of APC pathway resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!